Log in to your Inderes Free account to see all free content on this page.
Devyser Diagnostics
76.10 SEK
+0.26 %
Less than 1K followers
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.26 %
-15.63 %
-33.36 %
-33.48 %
-45.80 %
-26.47 %
+8.71 %
-
-14.49 %
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Read moreMarket cap
1.27B SEK
Turnover
485.23K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.4.
2026
Interim report Q1'26
6.5.
2026
General meeting '26
20.7.
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Redeye: Devyser (Q4 Interview): Redeye has interviewed CEO Jan Wahlström
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
